Asia Pacific Medical Isotope Market Size, Share & Trends Analysis Report By Type, By End User (Hospitals, Diagnostic Centers, and Research Institutes), By Application (Diagonostic, and Nuclear Therapy), By Country and Growth Forecast, 2023 - 2030

The Asia Pacific Medical Isotope Market would witness market growth of 9.3% CAGR during the forecast period (2023-2030).

The China market dominated the Asia Pacific Medical Isotope Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $663.8 million by 2030. The Japan market is registering a CAGR of 8.6% during (2023 - 2030). Additionally, The India market would experience a CAGR of 10% during (2023 - 2030).



Medical isotopes are used in dosimetry calculations to estimate radiation doses delivered to tissues and organs during diagnostic and therapeutic procedures. Dosimetry assessments help optimize treatment protocols, minimize radiation exposure to patients and healthcare personnel, and ensure the safe and effective use of isotopic therapies. Also, radiochemical purity, radionuclides purity, and sterility testing of medical isotopes are essential for ensuring product quality and safety. Quality control testing procedures comply with regulatory standards and guidelines to maintain the integrity and reliability of isotopic products.

Furthermore, the medical isotope market is characterized by several notable trends shaping the industry and driving innovation. Theranostics, integrating diagnostic imaging and therapeutic interventions using the same molecular target, is gaining traction in nuclear medicine. Theranostics approaches leverage medical isotopes for diagnostic imaging and targeted therapy, offering personalized treatment options and improved patient outcomes. This trend is particularly evident in developing radiopharmaceuticals for cancer treatment, where isotopes like lutetium-177 (Lu-177) and iodine-131 (I-131) are used for imaging and therapy.
The growth of the medical devices industry in India may lead to the establishment of more nuclear medicine facilities and departments nationwide. As per the data released by the India Brand Equity Foundation, by 2030, the medical equipment industry in India is anticipated to reach a valuation of $50 billion by 2030. Therefore, the growing medical device sector and the increasing elderly population in the region are propelling the market’s growth.

Based on Type, the market is segmented into Radioisotopes, and Stable Isotopes. Based on End User, the market is segmented into Hospitals, Diagnostic Centers, and Research Institutes. Based on Application, the market is segmented into Diagnostic, and Nuclear Therapy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

List of Key Companies Profiled

• Mallinckrodt PLC
• Bayer AG
• GE HealthCare Technologies, Inc.
• Canadian Nuclear Laboratories (Atomic Energy Of Canada Limited)
• ITM Isotope Technologies Munich SE
• Siemens Healthineers AG
• Eczacibasi-Monrol
• NorthStar Medical Radioisotopes, LLC
• Nordion Inc. (Sotera Health LLC)
• Iba SA

Market Report Segmentation

By Type

• Radioisotopes
• Stable Isotopes

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes

By Application

• Diagnostic
• Nuclear Therapy

By Country

• China
• Japan
• India
• South Korea
• Singapore
• Malaysia
• Rest of Asia Pacific